Clinical Trials On-Line - Physican: Leslie Popplewell

The following is a list of available studies directed by Leslie Popplewell, MD

Search results: 5 Clinical trial(s) found (Page 1 of 1 )

Results per page: 25 50 100 All

1-5 Trials

Jump to page:

Click here to generate a printer-friendly view

COH Protocol Number: 12263

ClinicalTrials.gov Number: NCT01611090

Principal Investigator: Leslie Popplewell, MD

Sponsor: Industrial

Title:

Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Summary
English

Full Eligibility
Criteria

PI's Profile

COH Protocol Number: 12260

ClinicalTrials.gov Number: NCT01729806

Principal Investigator: Leslie Popplewell, MD

Sponsor: NCI Approved External Peer Review

Title:

PHI-69, NCI #9197: A Phase I study of Ipilimumab in Combination with Rituximab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma

Summary
English

Full Eligibility
Criteria

PI's Profile

COH Protocol Number: 11083

ClinicalTrials.gov Number: NCT01402440

Principal Investigator: Leslie Popplewell, MD

Sponsor: Industrial

Title:

An Open-Label, Single-arm, Phase I study of AEB071 (a Protein Kinase C Inhibitor) in Patients with CD79-mutant Diffuse Large B-Cell Lymphoma

Summary
English

Summary
Spanish

Full Eligibility
Criteria

PI's Profile

COH Protocol Number: 10210

ClinicalTrials.gov Number: NCT00972478

Principal Investigator: Leslie Popplewell, MD

Sponsor: Cooperative Group

Title:

SWOG S0806: A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) In Combination with Rituximab-CHOP in Patients With Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)

Summary
English

Summary
Spanish

Full Eligibility
Criteria

PI's Profile

COH Protocol Number: 09174

ClinicalTrials.gov Number: NCT01318317

Principal Investigator: Leslie Popplewell, MD

Sponsor: NCI Approved External Peer Review

Title:

Phase I/II Study of Cellular Immunotherapy Using Central Memory-Enriched CD8+ T Cells Lentivirally Transduced to Express A CD19-Specific Chimeric Immunoreceptor Following Peripheral Blood Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

Summary
English

Summary
Spanish

Full Eligibility
Criteria

PI's Profile


Results per page: 25 50 100 All	1-5 Trials	Jump to page:

City of Hope

Page Title

Global Navigation